medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2018, Number S1

<< Back Next >>

Acta Med 2018; 16 (S1)

Treatment of hyperuricemia in chronic kidney disease

Ramírez SJC, Madero RM

Language: Spanish
References: 45
Page: 53-59
PDF size: 152.01 Kb.


ABSTRACT

Hyperuricemia may be a major contributor to the development or progression of chronic kidney disease. Although there is not a clear cutoff uric acid (UA) value associated to the risk for kidney damage, it appears to be an increased risk as UA rises. Lifestyle interventions such as exercise, weight reduction and low consumption of purine-rich meat or avoiding high fructose intake are recommended for all hyperuricemic patients. Urate lowering drugs as allopurinol or febuxostat may be an option as a renoprotective agent; yet, randomized clinical trials evaluating the safety and efficacy of these drugs are limited to a small number of single-center studies. Several ongoing clinical trials aim to evaluate the safety and efficacy of these drugs. As of today, there is insufficient evidence to recommend the widespread use of uric acid-lowering therapy to prevent or slow the progression of chronic kidney disease (CKD). The purpose of this review is to summarize the evidence and future perspective about the treatment of hyperuricemia in the prevention and progression of chronic kidney disease.


REFERENCES

  1. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009; 53 (5): 796-803.

  2. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: Which is chasing which? Nephrol Dial Transplant. 2013; 28 (9): 2221-2228.

  3. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis. 1999; 33 (2): 225-234.

  4. Eleftheriadis T, Golphinopoulos S, Pissas G, Stefanidis I. Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial. J Adv Res. 2017; 8 (5): 555-560.

  5. Kumagai T, Ota T, Tamura Y, Chang WX, Shibata S, Uchida S. Time to target uric acid to retard CKD progression. Clin Exp Nephrol. 2017; 21 (2): 182-192.

  6. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015; 33 (9): 1729-141.

  7. Chen JH, Yeh WT, Chuang SY, Wu YY, Pan WH. Gender-specific risk factors for incident gout: a prospective cohort study. Clin Rheumatol. 2012; 31 (2): 239-245.

  8. Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972; 15 (2): 189-192.

  9. Yamanaka H; Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011; 30 (12): 1018-1029.

  10. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011; 63 (1): 102-110.

  11. Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014; 29 (2): 406-413.

  12. Whelton A, MacDonald PA, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013; 125 (1): 106-114.

  13. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic non pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012; 64 (10): 1431-1446.

  14. Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010; 22 (2): 165-172.

  15. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000; 59 (7): 539-543.

  16. Lim JH, Kim YK, Kim YS, Na SH, Rhee MY, Lee MM. Relationship between serum uric acid levels, metabolic syndrome, and arterial stiffness in Korean. Korean Circ J. 2010; 40 (7): 314-320.

  17. Johnson RJ, Sautin YY, Oliver WJ, Roncal C, Mu W, Gabriela Sanchez-Lozada L et al. Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in Western society? J Comp Physiol B. 2009; 179 (1): 67-76.

  18. Madero M, Rodriguez-Castellanos FE, Jalal D, Villalobos-Martin M, Salazar J, Vazquez-Rangel A et al. A pilot study on the impact of a low fructose diet and allopurinol on clinic blood pressure among overweight and prehypertensive subjects: a randomized placebo controlled trial. J Am Soc Hypertens. 2015; 9 (11): 837-44.

  19. Zhao CC, Wang AP, Li LX, Li TT, Chen MY, Zhu Y et al. Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes. J Diabetes Complications. 2016; 30 (6): 1074-1080.

  20. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65 (10): 1312-1324.

  21. Dalbeth N, Stamp LK. Gout: Why compare the effectiveness of suboptimal gout management? Nat Rev Rheumatol. 2015; 11 (9): 506-507.

  22. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005; 76 (16): 1835-1847.

  23. Grabowski BA, Khosravan R, Vernillet L, Mulford DJ. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. J Clin Pharmacol. 2011; 51 (2): 189-201.

  24. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12 (2): R63.

  25. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010; 5 (8): 1388-1393.

  26. Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C et al. Uric acid in metabolic syndrome: From an innocent bystander to a central player. Eur J Intern Med. 2016; 29: 3-8.

  27. Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011; 22 (7): 1382-1389.

  28. Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012; 35 (3): 153-160.

  29. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015; 16 (1): 58.

  30. Talaat KM, El-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007; 27 (5): 435-440.

  31. Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015; 67 (4): 588-592.

  32. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011; 17 (1): 7-13.

  33. Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015; 66 (6): 945-950.

  34. Sánchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol. 2008; 295 (4): F1134-F1141.

  35. Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009; 48 (2): 188-194.

  36. Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014; 18 (6): 876-884.

  37. Fujimori S, Ooyama K, Ooyama H, Moromizato H. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease. Nucleosides Nucleotides Nucleic Acids. 2011; 30 (12): 1035-1038.

  38. Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011; 58 (1): 2-7.

  39. Van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin J Am Soc Nephrol. 2017; 12 (4): 700-710.

  40. Huang HY, Appel LJ, Choi MJ, Gelber AC, Charleston J, Norkus EP et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum. 2005; 52 (6): 1843-1847.

  41. National Research Infrastructure for Australia. Trial review - ANZCTR. 2016. Disponible en: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12613000513718

  42. Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y et al. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials. 2014; 15: 26.

  43. Maahs DM, Caramori L, Cherney DZI, Galecki AT, Gao C, Jalal D et al. Uric acid lowering to prevent kidney function loss in diabetes: the Preventing Early Renal Function Loss (PERL) allopurinol study. Curr Diab Rep. 2013; 13 (4): 550-559.

  44. Ling Wang. Compare the renal protective effects of febuxostat and benzbromarone —Tabular view— ClinicalTrials.gov [Internet]. [cited 2017 Jul 29]. Disponible en: https://clinicaltrials.gov/ct2/show/record/NCT02338323?term=febuxostat&recrs=a&rank=3

  45. AstraZeneca. Intensive uric acid lowering with RDEA3170 and febuxostat in patients with albuminuria —Tabular view— ClinicalTrials.gov [Internet]. [Cited 2017 Jul 29]. Disponible en: https://clinicaltrials.gov/ct2/show/record/NCT03118739?term=febuxostat&recrs=a&rank=4




2020     |     www.medigraphic.com